Epidarex Portfolio News

EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY


Category: Epidarex Portfolio News

Edinburgh Molecular Imaging Commences Phase II European Cancer Trial

Novel Compound with Potential for Early Detection and to Guide Treatment of Colorectal Cancer Edinburgh, UK, September 20, 2017 – Edinburgh Molecular Imaging (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces it has commenced a pivotal Phase IIb clinical trial…

Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration

Statistically Significant Slowing of Disease Progression Seen at 12 Months Louisville, Kentucky, August 24, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced that its complement C3 inhibitor, APL-2, met…

Apellis Pharmaceuticals Announces $60 Million Series E Financing

Funding Will Advance Trials of APL-2 in Paroxysmal Nocturnal Hemoglobinuria. Louisville, Kentucky, August 10, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today announced the closing of a $60 million Series E preferred…

Aclaris Therapeutics Acquires Confluence Life Sciences, Inc.

Expands pipeline of medicines for the potential treatment of patients with autoimmune disorders. Malvern, PA, August 8, 2017 – Aclaris Therapeutics, Inc. (“Aclaris”) (NASDAQ: ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in…